Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA 3165 (MIR3165) is a short, non-coding RNA molecule classified as a microRNA (miRNA), typically 20-24 nucleotides in length[1]. Like other miRNAs, MIR3165 is transcribed by RNA polymerase II as part of a primary transcript, processed by Drosha (in the nucleus) and Dicer (in the cytoplasm) enzymes to generate a mature miRNA duplex[1][3]. The mature MIR3165 is incorporated into the RNA-induced silencing complex (RISC), where it binds target mRNAs primarily through imperfect base pairing, causing translational inhibition or destabilization of the mRNA[1][2][5]. Although the general functions of miRNAs include roles in cell differentiation, proliferation, apoptosis, and gene expression regulation, there are no specific disease associations, therapeutic targeting, or interacting drugs currently known or annotated for MIR3165[1][5]. The biological specificity and clinical relevance of MIR3165 remain uncharacterized in current biomedical databases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA 3165 (MIR3165).